Evidence map›Paper›PMID 25597442›Full record

ReviewCurrent opinion in immunology2015

Suppression of antigen presentation by IL-10.

Sharad K Mittal, Paul A Roche

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

183 citing papers in PubMed, 1 synthesis or guideline pooled it, 294 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Fusobacterium nucleatum, succinate signaling, and immunotherapy resistance in colorectal cancer: clinical relevance and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Antigen-specific immunotherapy with a CD4Nature communications · 2026
    Article
  17. Review
  18. Article
  19. Review
  20. Review

123 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sharad K MittalExperimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Paul A RocheExperimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States. Electronic address: paul.roche@nih.gov.
National Institutes of Health · US

Funding

Regulation of MHC Class II Trafficking in Antigen Presenting CellsZIABC009404 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROCHE, PAUL · 2009 to 2025
$17.9M
Regulation of MHC Class II Trafficking in Antigen Presenting CellsZ01BC009404 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROCHE, PAUL · 1996 to 2008
$1.8M
Intramural NIH HHS Z01 BC009404Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Regulated antigen presentation to immune cells determines the effectiveness of an immune response. IL-10 is an immunosuppressive cytokine that regulates immune responses by inhibiting the ability of APCs to present antigens to T cells in a variety of ways. The mechanisms of IL-10-mediated immunosuppression include interference in TLR-mediated or IFNγ-mediated dendritic cell (DC) and macrophage activation as well as direct induction of genes that suppress APC function. In this review we will discuss current studies exploring the molecular mechanisms by which IL-10 suppresses APC function.

Indexed as

Antigen PresentationAnimalsDendritic CellsHumansImmune ToleranceInterleukin-10PhagocytesSignal TransductionToll-Like ReceptorsInterleukin-10Toll-Like Receptors

Identifiers

PMID25597442
PMCPMC4444374
OpenAlexW2034807686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.